MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells
Open Access
- 21 June 2017
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 36 (1) , 1-10
Abstract
MicroRNAs (miRs) are involved in tumor progression by regulating tumor cells and tumor microenvironment. MiR21 is overexpressed in diffuse large B-cell lymphoma (DLBCL) and its biological impact on tumor microenvironment remains unclear. MiR21 was assessed by quantitative RT-PCR in patients with newly diagnosed DLBCL. The mechanism of action of miR21 on lymphoma progression and tumor angiogenesis was examined in vitro in B-lymphoma cell lines and in vivo in a murine xenograft model. Serum miR21 was significantly elevated in patients and associated with advanced disease stage, International Prognostic Index indicating intermediate-high and high-risk, and increased tumor angiogenesis. When co-cultured with immune cells and endothelial cells, miR21-overexpressing B-lymphoma cells were resistant to chemotherapeutic agents, but sensitive to Bcl-2 inhibitor ABT-199, irrespective of Bcl-2 expression on lymphoma cells. In both co-culture systems of Bcl-2positive and Bcl-2negative B-lymphoma cells, miR21 induced inducible co-stimulator (ICOS) expression on regulatory T (Treg) cells. Through crosstalking with Treg cells by ICOS ligand (ICOSL), endothelial cells were activated, resulting in stimulation of Bcl-2 expression and vessel formation. ABT-199 directly targeted Bcl-2 on endothelial cells, induced endothelial cell apoptosis and inhibited tumor angiogenesis. In a murine xenograft model established with subcutaneous injection of B-lymphoma cells, ABT-199 particularly retarded the growth of miR21-overexpressing tumors, consistent with the induction of endothelial cell apoptosis and inhibition of tumor angiogenesis. As a serum oncogenic biomarker of B-cell lymphoma, miR21 indicated B-lymphoma cell sensitivity to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells.Keywords
Funding Information
- National Natural Science Foundation of China (81325003, 81520108003, 81670716 and 81201863)
- Shanghai Commission of Science and Technology (14430723400, 14140903100 and 16JC1405800)
- Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support (20152206 and 20152208)
- Chang Jiang Scholars Program
- Collaborative Innovation Center of Systems Biomedicine
- The Samuel Waxman Cancer Research Foundation
This publication has 38 references indexed in Scilit:
- ICOSL expression in human bone marrow-derived mesenchymal stem cells promotes induction of regulatory T cellsScientific Reports, 2017
- miR-21 regulates tumor progression through the miR-21-PDCD4-Stat3 pathway in human salivary adenoid cystic carcinomaLaboratory Investigation, 2015
- MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphomaOncotarget, 2015
- Clinical significance and detection of microRNA‐21 in serum of patients with diffuse large B‐cell lymphoma in Chinese populationEuropean Journal of Haematology, 2014
- Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphomaJournal of Hematology & Oncology, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- MicroRNA–target interactions: new insights from genome‐wide approachesAnnals of the New York Academy of Sciences, 2012
- Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphomaAnnals of Hematology, 2011
- BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic AgentsCancer Cell, 2007
- Tregs and rethinking cancer immunotherapyJournal of Clinical Investigation, 2007